NUMA1 and urinary bladder carcinoma: Relatively few urinary biomarkers have been approved by the FDA with examples including nuclear matrix protein 22 (NMP22) and bladder tumor associated antigen (complement factor H related protein/complement factor H) for use in bladder cancer surveillance 4 and there is now an enhanced effort to use proteomic technologies to identify new biomarkers.